TY - JOUR
T1 - Interval cancers in a FOBT-based colorectal cancer population screening programme
T2 - Implications for stage, gender and tumour site
AU - Steele, R.J.C.
AU - McClements, P.
AU - Watling, C.
AU - Libby, G.
AU - Weller, D.
AU - Brewster, D.H.
AU - Black, R.
AU - Carey, F.A.
AU - Fraser, C.G.
N1 - MEDLINE® is the source for the MeSH terms of this document.
PY - 2012/3/1
Y1 - 2012/3/1
N2 - Background: Between 2000 and 2007, a demonstration pilot of biennial guaiac faecal occult blood test (GFOBT) screening was carried out in Scotland. Methods: Interval cancers were defined as cancers diagnosed within 2 years (ie, a complete screening round) of a negative GFOBT. The stage and outcome of the interval cancers were compared with those arising contemporaneously in the non-screened Scottish population. In addition, the gender and site distributions of the interval cancers were compared with those in the screen-detected group and the non-screened population. Results: Of the cancers diagnosed in the screened population, interval cancers comprised 31.2% in the first round, 47.7% in the second, and 58.9% in the third, although this was due to a decline in the numbers of screen-detected cancers rather than an increase in interval cancers. There were no consistent differences in the stage distribution of interval cancers and cancers from the non-screened population, and, in all three rounds, both overall and cancer-specific survival were significantly better for patients diagnosed with interval cancers (p
AB - Background: Between 2000 and 2007, a demonstration pilot of biennial guaiac faecal occult blood test (GFOBT) screening was carried out in Scotland. Methods: Interval cancers were defined as cancers diagnosed within 2 years (ie, a complete screening round) of a negative GFOBT. The stage and outcome of the interval cancers were compared with those arising contemporaneously in the non-screened Scottish population. In addition, the gender and site distributions of the interval cancers were compared with those in the screen-detected group and the non-screened population. Results: Of the cancers diagnosed in the screened population, interval cancers comprised 31.2% in the first round, 47.7% in the second, and 58.9% in the third, although this was due to a decline in the numbers of screen-detected cancers rather than an increase in interval cancers. There were no consistent differences in the stage distribution of interval cancers and cancers from the non-screened population, and, in all three rounds, both overall and cancer-specific survival were significantly better for patients diagnosed with interval cancers (p
UR - http://www.scopus.com/inward/record.url?partnerID=yv4JPVwI&eid=2-s2.0-84857798015&md5=51126474df03e827f6ebb04dd4945468
U2 - 10.1136/gutjnl-2011-300535
DO - 10.1136/gutjnl-2011-300535
M3 - Article
AN - SCOPUS:84857798015
SN - 0017-5749
VL - 61
SP - 576
EP - 581
JO - Gut
JF - Gut
IS - 4
ER -